Search clinical trials for: Inhibitors, Angiogenesis

Total 6038 results

Chongqing University Cancer Hospital

Recruiting

Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi

Ovarian Cancer

China
University Hospital, Grenoble
NETRIS Pharma

Recruiting

Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC (Liver-NET1)

Hepatocellular Carcinoma

France
Fudan University

Recruiting

VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer

Colorectal Cancer

China
Henan Provincial People's Hospital

Not yet recruiting

Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

Recurrent Glioblastoma

China
University of Texas Southwestern Medical Center
Genentech, Inc.

Recruiting

LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC (LOST-B)

Hepatocellular Carcinoma

United States
Anhui Chest Hospital

Not yet recruiting

Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Yongchang Zhang

Recruiting

Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT

Hepatocellular Carcinoma Non-resectable

China
Centre Hospitalier Universitaire de Besancon
GERCOR - Multidisciplinary Oncology Cooperative Group; PRODIGE

Recruiting

Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma (TERTIO)

Hepatocellular Carcinoma

France
Hebei Medical University Fourth Hospital

Recruiting

Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

Solid Tumor

China
Seoul National University Bundang Hospital
Roche Pharma AG; Korean Cancer Study Group

Recruiting

KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II (KOSMOSII)

Solid Tumor | Metastatic Cancer | Advanced Solid Tumor

Korea, Republic of
RenJi Hospital

Not yet recruiting

A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus

Uremic Pruritus | Haemodialysis | Thalidomide
University of Oklahoma
GlaxoSmithKline

Recruiting

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation (ARID1A)

Recurrent Ovarian Carcinoma | Recurrent Endometrial Carcinoma | ARID1A Gene Mutation

United States
Henan Provincial People's Hospital

Not yet recruiting

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma

Astrocytoma of Brain

China
Celgene

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)

Relapsed or Refractory Multiple Myeloma

United States, Australia, Italy, China, Spain, Germany, Romania, Korea, Republic of, Japan, United Kingdom, Czechia, Finland, France, Greece, Argentina, Belgium, Austria, Portugal, Israel, New Zealand, Poland, Brazil, Turkey, Canada, Ir... and more
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss

Branch Retinal Vein Occlusion

China
Khairallah Moncef

Recruiting

Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy

Proliferative Diabetic Retinopathy | Vitreous Hemorrhage | Tractional Retinal Detachment

Tunisia
National Cancer Centre, Singapore
National University Hospital, Singapore; Singapore General Hospital; Tan Tock... and other collaborators

Recruiting

Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma (EMPHASIS)

Hepatocellular Carcinoma

Singapore
Zhejiang Cancer Hospital

Recruiting

Radiotherapy Combined With Endostatin and Capecitabine for NPC

Nasopharyngeal Carcinoma

China
Henan Provincial People's Hospital

Recruiting

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma

Oligodendroglioma

China
Henan Provincial People's Hospital

Not yet recruiting

Study on Gene Evolution in Glioma Under Stress Therapy

Genetic Change

China
Samsung Medical Center

Recruiting

Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone (KMM2002)

Multiple Myeloma

Korea, Republic of
Tianjin Medical University Cancer Institute and...

Recruiting

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

Non Small Cell Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

EGFR Gene Mutation | Lung Adenocarcinoma Stage III | Lung Adenocarcinoma Stage IV

China
Henan Provincial People's Hospital

Not yet recruiting

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma

Glioblastoma

China
The Affiliated Hospital of Qingdao University

Not yet recruiting

SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression

DLBCL

China
Samsung Medical Center

Recruiting

Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT (KMM1911)

Multiple Myeloma

Korea, Republic of
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

Multiple Myeloma | ISS Stage III Plasma Cell Myeloma

United States
Dong-A University Hospital
Amgen

Not yet recruiting

Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
Taipei Medical University
Mackay Memorial Hospital

Not yet recruiting

Interactive Hand Exercise Game on Grip Strength and Vascular Maturation

Muscle Weakness | Angiogenesis

Taiwan
Sun Yat-sen University
The First Affiliated Hospital with Nanjing Medical University; West China Hospital and other collaborators

Recruiting

Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation (EAGLE)

Non-Small Cell Lung Cancer

China
AstraZeneca
Daiichi Sankyo

Recruiting

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Cancer | Biliary Tract Cancer | Metastatic Castration-resistant Prostate Cancer

Spain, China, Korea, Republic of, Canada, Italy, Poland, Turkey, United Kingdom, Japan, Taiwan, United States, France, Germany, Switzerland
Jiangxi Provincial People's Hopital

Not yet recruiting

Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis

Dermatomyositis

China
Abramson Cancer Center at Penn Medicine

Recruiting

SBRT With Atezo/Bev for HCC

Hepatocellular Carcinoma

United States
Georgetown University
Genentech, Inc.; Natera, Inc.

Recruiting

Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD-GI)

Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | Gallbladder Adenocarcinoma | Adenocarcinoma of Biliary Tract

United States
Leap Therapeutics, Inc.

Recruiting

Phase 2 Study of DKN-01 in Colorectal Cancer (DeFianCe)

Colorectal Cancer | Colorectal Cancer Metastatic | Colo-rectal Cancer | Colorectal Adenocarcinoma

United States, Korea, Republic of, Germany
Sinocelltech Ltd.

Recruiting

This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD

Wet Age-related Macular Degeneration

China
RenJi Hospital

Recruiting

Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.

Overall Survival | Progression Free Survival | Maintenance

China
Peking University People's Hospital
Qingdao Municipal Hospital

Recruiting

Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement (SPODUMENE)

Multiple Myeloma

China
Hoffmann-La Roche

Recruiting

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER)

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

Spain, Germany, Croatia, Israel, Japan, United Kingdom, United States, Italy, Switzerland, France, Canada, Australia, Singapore, Puerto Rico, United Arab Emirates, Bulgaria, Chile, Czechia
Irene Ghobrial, MD
Janssen Research & Development, LLC

Recruiting

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Multiple Myeloma | Smoldering Multiple Myeloma | High-risk Smoldering Multiple Myeloma

United States
Sun Yat-sen University

Recruiting

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

Stage III Non-small Cell Lung Cancer

China
St. Jude Children's Research Hospital

Recruiting

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Hepatocellular Carcinoma | Pediatric Cancer | Malignant Solid Tumor | Fibrolamellar Carcinoma | Pediatric Solid Tumor | Refractory Solid Tumor

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

Colorectal Cancer

United States, Spain, Japan
Centre Hospitalier Universitaire de Besancon

Recruiting

Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer (REPROGRAM-02)

Metastatic Colorectal Cancer

France
TOT Biopharm Co., Ltd.
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

Recruiting

TAB014 Compared to Lucentis® in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration

China
Shanghai Chest Hospital

Recruiting

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

Non-small Cell Lung Cancer | Minimal Residual Disease | Immunotherapy | Anti-angiogenesis

China
Janssen Research & Development, LLC

Recruiting

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (MonumenTAL-3)

Relapsed or Refractory Multiple Myeloma

United States, Italy, Korea, Republic of, Taiwan, China, Germany, Turkey, Japan, France, United Kingdom, Brazil, Spain, Czechia, Israel, Belgium, Greece, Poland, Netherlands
Rajshekhar Chakraborty, MD
Genentech, Inc.

Recruiting

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

AL Amyloidosis

United States
Peking Union Medical College Hospital

Recruiting

Lenalidomide in the Treatment of Mucosal Behçet's Syndrome

Oral Ulcer

China
Affiliated Cancer Hospital & Institute of Guangzhou...

Not yet recruiting

Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC

Non Small Cell Lung Cancer | Endostatin

China

Search clinical trials for: Inhibitors, Angiogenesis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations